Active surveillance is an excellent management technique for identifying patients with progressive low-risk papillary thyroid microcarcinoma requiring surgical treatment
Endocrine Journal · 2023
DOI: 10.1507/endocrj.ej22-0559 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Journal, 2023. Verfasst von Makoto Fujishima und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan. Hauptthemen laut MEDLINE: Thyroidectomy, Thyroid Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan.
- Department of Internal Medicine, Kuma Hospital, Kobe 650-0011, Japan.
- Department of Head and Neck, Kuma Hospital, Kobe 650-0011, Japan.
Zitieren
APA
Fujishima, M., Miyauchi, A., Ito, Y., Kudo, T., Noda, T., Sano, T., Sasaki, T., Kishi, T., & Nakamura, T. (2023). Active surveillance is an excellent management technique for identifying patients with progressive low-risk papillary thyroid microcarcinoma requiring surgical treatment. Endocrine Journal. https://doi.org/10.1507/endocrj.ej22-0559
Vancouver
Fujishima M, Miyauchi A, Ito Y, Kudo T, Noda T, Sano T, et al. Active surveillance is an excellent management technique for identifying patients with progressive low-risk papillary thyroid microcarcinoma requiring surgical treatment. Endocrine Journal. 2023. doi:10.1507/endocrj.ej22-0559
BibTeX
@article{Fujishima2023,
author = {Fujishima, Makoto and Miyauchi, Akira and Ito, Yasuhiro and Kudo, Takumi and Noda, Takuya and Sano, Tsutomu and Sasaki, Takahiro and Kishi, Taketoshi and Nakamura, Tomohiko},
title = {Active surveillance is an excellent management technique for identifying patients with progressive low-risk papillary thyroid microcarcinoma requiring surgical treatment},
journal = {Endocrine Journal},
year = {2023},
doi = {10.1507/endocrj.ej22-0559}
}
EUVIMED